| dc.contributor.author | Ramokolo, Vundli | |
| dc.contributor.author | Goga, Ameena E. | |
| dc.contributor.author | Doherty, Tanya | |
| dc.date.accessioned | 2021-08-20T08:22:14Z | |
| dc.date.available | 2021-08-20T08:22:14Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Ramokolo, V. et al. (2017). In utero art exposure and birth and early growth outcomes among HIV-exposed uninfected infants attending immunization services: Results from national pmtct surveillance, South Africa. Open Forum Infectious Diseases, 4(4), 1–10. https://doi.org/10.1093/ofid/ofx187 | en_US |
| dc.identifier.issn | 2328-8957 | |
| dc.identifier.uri | 10.1093/ofid/ofx187 | |
| dc.identifier.uri | http://hdl.handle.net/10566/6519 | |
| dc.description.abstract | . Despite the recognized benefit of antiretroviral therapy (ART) for preventing and treating HIV, some studies have
reported adverse birth outcomes with in utero ART exposure. We evaluated the effect of infant in utero HIV and ART exposure on
preterm delivery (PTD), low birth weight (LBW), small for gestational age (SGA), and underweight for age (UFA) at 6 weeks.We surveyed 6179 HIV-unexposed-uninfected (HUU) and 2599 HIV-exposed-uninfected (HEU) infants. HEU infants
were stratified into 3 groups: ART, Zidovudine alone, and no antiretrovirals (None). The ART group was further stratified to explore
pre- or postconception exposure. Multivariable logistic regression evaluated effects of HIV and ARV exposure on the outcomes. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Oxford University Press | en_US |
| dc.subject | Antiretroviral therapy | en_US |
| dc.subject | Birth outcome | en_US |
| dc.subject | HIV | en_US |
| dc.subject | South Africa | en_US |
| dc.subject | Infants | en_US |
| dc.title | In utero art exposure and birth and early growth outcomes among HIV-exposed uninfected infants attending immunization services: Results from national pmtct surveillance, South Africa | en_US |
| dc.type | Article | en_US |
